DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $355 | -30.1% | 17,200 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $508 | +56.3% | 17,200 | +22.0% | 0.00% | +50.0% |
| Q1 2023 | $325 | -17.1% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $392 | -99.9% | 14,100 | +5.2% | 0.00% | -33.3% |
| Q3 2022 | $411,000 | +4.3% | 13,400 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $394,000 | +3.7% | 13,400 | +13.6% | 0.00% | +50.0% |
| Q1 2022 | $380,000 | -52.7% | 11,800 | -34.4% | 0.00% | -50.0% |
| Q4 2021 | $803,000 | -11.6% | 18,000 | 0.0% | 0.00% | -20.0% |
| Q3 2021 | $908,000 | -35.7% | 18,000 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $1,412,000 | +35.9% | 18,000 | -1.1% | 0.01% | +16.7% |
| Q1 2021 | $1,039,000 | -12.0% | 18,200 | +29.1% | 0.01% | -14.3% |
| Q4 2020 | $1,181,000 | +133.9% | 14,100 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $505,000 | -26.0% | 14,100 | -50.0% | 0.00% | +33.3% |
| Q2 2020 | $682,000 | – | 28,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |